Therapeutic ultrasound for venous leg ulcers by Cullum, Nicky et al.
Cochrane Database of Systematic Reviews
Therapeutic ultrasound for venous leg ulcers (Review)
Cullum N, Al-Kurdi D, Bell-Syer SEM
Cullum N, Al-Kurdi D, Bell-Syer SEM.
Therapeutic ultrasound for venous leg ulcers.
Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD001180.
DOI: 10.1002/14651858.CD001180.pub3.
www.cochranelibrary.com
Therapeutic ultrasound for venous leg ulcers (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
9RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
14ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
17DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Ultrasound (any frequency) vs no ultrasound, Outcome 1 Proportion of ulcers healed at 7 or 8
weeks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Analysis 2.1. Comparison 2 High frequency US vs no ultrasound, Outcome 1 Proportion of ulcers completely healed
during study follow up (varying durations of follow up). . . . . . . . . . . . . . . . . . . . 35
Analysis 2.2. Comparison 2 High frequency US vs no ultrasound, Outcome 2 Proportion ulcers completely healed at 3
weeks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Analysis 2.3. Comparison 2 High frequency US vs no ultrasound, Outcome 3 Proportion ulcers completely healed at 7 or
8 weeks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Analysis 2.4. Comparison 2 High frequency US vs no ultrasound, Outcome 4 Proportion of ulcers completely healed at 12
weeks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Analysis 3.1. Comparison 3 Low frequency US vs no ultrasound, Outcome 1 Proportion ulcers completely healed at 8 - 12
weeks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
39APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
45INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iTherapeutic ultrasound for venous leg ulcers (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Therapeutic ultrasound for venous leg ulcers
Nicky Cullum1, Deyaa Al-Kurdi2, Sally EM Bell-Syer3
1School ofNursing,Midwifery andSocialWork,University ofManchester,Manchester,UK. 2TheCochraneWoundsGroup,University
of York, York, UK. 3Department of Health Sciences, University of York, York, UK
Contact address: Nicky Cullum, School of Nursing, Midwifery and Social Work, University of Manchester, Jean McFarlane Building,
Oxford Road, Manchester, M13 9PL, UK. nicky.cullum@manchester.ac.uk.
Editorial group: Cochrane Wounds Group.
Publication status and date: Edited (no change to conclusions), published in Issue 12, 2011.
Review content assessed as up-to-date: 7 May 2010.
Citation: Cullum N, Al-Kurdi D, Bell-Syer SEM. Therapeutic ultrasound for venous leg ulcers. Cochrane Database of Systematic
Reviews 2010, Issue 6. Art. No.: CD001180. DOI: 10.1002/14651858.CD001180.pub3.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Venous leg ulcers pose a significant burden for patients and healthcare systems. Ultrasound (US) may be a useful treatment for these
ulcers.
Objectives
To determine whether US increases the healing of venous leg ulcers.
Search methods
We searched the Cochrane Wounds Group Specialised Register (searched 24 February 2010); The Cochrane Central Register of
Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2010); Ovid MEDLINE (1950 to February Week 2 2010); In-Process
& Other Non-Indexed Citations (searched 24 February 2010); Ovid EMBASE 1980 to 2010 Week 07; EBSCO CINAHL 1982 to
24 February 2010.
Selection criteria
Randomised controlled trials (RCTs) comparing US with no US.
Data collection and analysis
Two authors independently assessed the search results and selected eligible studies. Details from included studies were summarised
using a data extraction sheet, and double-checked. We tried to contact trial authors for missing data.
Main results
Eight trials were included; all had unclear, or high, risks of bias, with differences in duration of follow-up, and US regimens. Six trials
evaluated high frequency US and five of these reported healing at 7 - 8 weeks. Significantly more patients healed with US than without
it at 7 - 8 weeks (pooled RR 1.4, 95% CI 1.0 to 1.96), but later assessments at 12 weeks showed the increased risk of healing with US
was no longer statistically significant (pooled RR 1.47, 95% CI 0.99 to 2.20). One poor-quality study of high-frequency US found no
evidence of an effect on healing after three weeks’ treatment.
Two trials evaluated low frequency US and reported healing at different time points. Both trials reported no evidence of a difference in
the proportion of ulcers healed with US compared with no US: both were significantly underpowered.
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Authors’ conclusions
The trials evaluating US for venous leg ulcers are small, poor-quality and heterogeneous. There is no reliable evidence that US hastens
healing of venous ulcers. There is a small amount of weak evidence of increased healing with US, but this requires confirmation in
larger, high-quality RCTs. There is no evidence of a benefit associated with low frequency US.
P L A I N L A N G U A G E S U M M A R Y
Ultrasound therapy used for healing venous (varicose) leg ulcers and to improve symptoms
Venous leg ulcers are common, especially in the elderly. They are caused by damage or blockages in the veins of the legs, which in
turn lead to pooling of blood and increased pressure in these veins. Eventually, these changes can damage the skin and lead to ulcer
formation.
Compression with stockings or bandages is the most widely used, and acceptable, treatment for venous leg ulcers. Ultrasound has been
used as an additional intervention, especially for difficult, long-standing ulcers. The mechanisms by which ultrasound waves interact
with healing tissues are not fully understood. We conducted a review to establish whether ultrasound speeds the healing and improve
symptoms of venous leg ulcers, and examined all the available evidence frommedical trials. This showed that there is no strong evidence
that ultrasound hastens ulcer healing. There is, however, some weak evidence from poor-quality research that high-frequency ultrasound
may increase the healing of venous leg ulcers. This finding, however, requires confirmation in larger and rigorously conducted medical
trials before we can be certain that it is true and can be trusted. There is no evidence that low frequency ultrasound improves the healing
of venous leg ulcers.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
High frequency US compared to no ultrasound for venous leg ulcers
Patient or population: patients with venous leg ulcers
Settings:
Intervention: High frequency US
Comparison: no ultrasound
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
no ultrasound High frequency US
Proportion of ulcers
completely healed at 12
weeks - High-frequency
US (losses as failures)
clinical judgement
Study population1 RR 1.47
(0.99 to 2.2)
152
(2 studies)
⊕©©©
very low2,3
32 per 100 47 per 100
(32 to 71)
Medium risk population1
33 per 100 49 per 100
(33 to 73)
High risk population1
50 per 100 74 per 100
(50 to 100)
Proportion ulcers com-
pletely healed at 7 or 8
weeks - Losses as fail-
ures
Study population RR 1.4
(1 to 1.96)
341
(5 studies)
⊕©©©
very low4,5
24 per 100 34 per 100
(24 to 47)
Medium risk population
3
T
h
e
ra
p
e
u
tic
u
ltra
so
u
n
d
fo
r
v
e
n
o
u
s
le
g
u
lc
e
rs
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
1
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
22 per 100 32 per 100
(22 to 44)
HRQoL - not reported See comment See comment Not estimable - See comment Venous leg ulcers ad-
versely affect quality of
life however no study
measured (or reported)
this
Pain - not reported See comment See comment Not estimable - See comment Venous leg ulcers can
be extremely painful how-
ever no study measured
pain in a valid, reliable
way
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 High risk of healing at 12 weeks of 50% taken from a large, well conducted RCT where patients all received best practice care (Iglesias
et al). Low risk taken from lowest control group healing rate in these trials.
2 Both studies at unclear or high risk of bias.
3 Only 60 participants across the two trials reached the endpoint (complete healing).
4 All studies at high or unclear risk of bias. Only one study described concealed allocation (Callam) and none used blinded assessment
of the point at which healing occurred.
5 Studies were small with a total of only 98 participants reaching the endpoint
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B A C K G R O U N D
Description of the condition
The prevalence of active venous leg ulceration has been estimated
at 1.5/1000 (Callam 1986), it is higher among women and in-
creases with age (Callam 1985; Margolis 2002). The incidence
of venous ulceration in the elderly population has been estimated
at 0.76/100 person-year for men, and 1.42/100 person-year for
women (Margolis 2002).
Venous disease, including ulceration, constitutes a considerable
economic burden, accounting for 2% to 3% of healthcare budget
expenditure (Lafuma 1994; Ruckley 1997). Ulcer management
is costly (Bosanquet 1992) due to its chronic, recurring nature
(Callam 1986) and the need for frequent changes of dressing,
home visits, and hospitalisation (Olin 1999). Younger people of
working age also experience venous leg ulcers (Nelzen 1994), and
their reduced ability to participate in the labour market adds to the
economic impact of this disease (Lafuma 1994; Ruckley 1997).
Venous insufficiency is a term used to describe the lack of flow (sta-
sis) of venous blood in the lower limbs. The stasis and pooling of
blood in the venous system can be caused by dysfunctional valves
of the superficial or deep venous system, deep venous outflow
obstruction, or failure of the muscular pump mechanism of the
lower limbs (Valencia 2001). The exact pathophysiology behind
skin damage and ulcer formation in venous insufficiency is not
known; multiple hypotheses include white cell trapping, growth
factor trapping, pericapillary fibrin cuffs and fibrinolytic abnor-
malities (Valencia 2001).
Description of the intervention
The role of therapeutic ultrasound (US) has been explored in a
diverse array of conditions including osteoarthritis (Robinson
2001), rheumatoid arthritis (Casimiro 2002), ankle sprains (Van
der Windt 2002), pelvic and perineal pain (Hay-Smith 1998),
fractures (Busse 2009) and pressure ulcers (Akbari Sari 2006).
Therapeutic US has been proposed as a solution for venous leg
ulcers that are difficult to treat, and a systematic review is required
in order to summarise the results of existing studies accurately.
A typical therapeuticUSdevice consists of a generator that is linked
to an applicator head; this enables delivery of multiple frequencies
in either a continuous, or pulsed, manner. US is either adminis-
tered by direct application of the applicator head to the skin, usu-
ally with a coupling agent (direct US) (Hart 1998), or indirectly,
where the affected area is placed in a constant-temperature water
bath and the US administered through the water. Directly-applied
US is usually applied to the skin around the ulcer (periulcer skin)
rather than directly to the ulcer.Most trials used a pulsed US, with
a frequency range of 1 to 3MHz, and intensity of 0.5 to 1W/cm²,
for a duration of 5 to 10 minutes, although there does not seem
to be any evidence base for this particular regimen (Hart 1998).
How the intervention might work
The effects of therapeutic US are classified as either thermal or
non-thermal on the basis of the proposed physiological effects
(Baker 2001; Dyson 1987; Johns 2002; Ter Haar 1999).
Thermal effects
The thermal effects of US are achieved by using a higher intensity
application to achieve, and maintain, a rise in tissue temperature
to around 40°C (Dyson 1987). Thermal effects have been hypoth-
esized as being capable of increasing blood flow (Dyson 1987),
although some trials concluded that there was no obvious effect
(Hansen 1973; Hogan 1982; Paul 1955). It has also been sug-
gested that the thermal effects of US produce favourable changes
in the physical attributes of collagen-rich structures (Dyson 1987;
Ter Haar 1999), although results of research vary in this regard
(Enwemka 1990; Larsen 2005).
Non-thermal effects
The non-thermal effects of US are thought to be due to two US-
induced phenomena:
1) acoustic streaming: flow and displacement of particles in a fluid
medium due to the physical forces of sound waves (Baker 2001;
Johns 2002; Ter Haar 1999). Streaming can be further classified
into bulk streaming or microstreaming, the latter being more me-
chanically powerful.
2) cavitation: the formation and behaviour ofmicroenvironmental
gases within a fluid medium under the influence of sound waves
(Baker 2001; Johns 2002; Ter Haar 1999).
Multiple in vitro studies investigating the non-thermal effect of
therapeutic US on the different elements of tissue healing have
been conducted. US has been reported as: potentiating enzymatic
fibrinolysis (Francis 1992; Olsson 1994); stimulating protein syn-
thesis (Doan 1999; Ross 1983; Webster 1978); inducing an in-
crease in cell proliferation (Doan 1999); inducing release of pre-
formed substances from cells (Ito 2000; Young 1990a); stimulat-
ing inflammatory cells (Maxwell 1994; Young 1990a); increasing
deposition of collagen (Byl 1992); and promoting formation of
new blood vessels (angiogenesis) (Young 1990b). It is not clear,
however, whether these effects can be reproduced in vivo, and
while some argue that the biophysical phenomena (cavitation and
acoustic streaming) do not occur in vivo (Baker 2001), there are
conflicting results from different studies (Carstensen 2000; Ter
Haar 1981). Furthermore, another study encountered extreme dif-
ficulty in observing the occurrence of these phenomena reliably
(Crum 1992). Further analysis and discussion of this issue was
felt to be out of the scope of this review, but additional helpful
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information can be found in the following reviews (Baker 2001;
Johns 2002).
Why it is important to do this review
The effectiveness of US in enhancing the healing of tissue both in
vivo and in vitro is uncertain. ACochrane review ofUS for treating
pressure ulcers concluded that there was no evidence of significant
benefit (Akbari Sari 2006). The delivery ofUS requires investment
of health resources and patient time, whilst the equipment can
be a potential vector for hospital-acquired (nosocomial) infection
(Schabrun 2006), therefore, we need to establish whether it speeds
the healing of venous ulcers. In the face of these uncertainties, an
up to date review investigating the possible therapeutic effects of
US in venous leg ulcers is important.
O B J E C T I V E S
The review aimed to determine whether venous leg ulcers treated
with US heal more quickly than those not treated with US.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For this update, we have included only randomised controlled
trials (RCTs) that evaluated the effectiveness of US therapy on the
healing of venous leg ulcers. Previous versions of the review also
included quasi-randomised studies but we now deem these to be
at high risk of selection bias and potentially misleading.
Types of participants
We included trials involving people of any age, and in any care
setting, described as having leg ulcers of venous aetiology. As the
method of obtaining a differential diagnosis of the ulcer varies, we
used study authors’ definitions of what constituted a venous leg
ulcer.
Trials that recruited people with arterial, diabetic or rheumatoid
ulcerationwere only included if the results for patients with venous
ulcers were presented separately.
Types of interventions
The primary intervention was US. Eligible comparison interven-
tions were “no US” in the form of usual care, sham US, or a com-
bination of the two.
Types of outcome measures
Primary outcomes
We sought RCTs which reported objective measures of healing
such as time to ulcer healing; proportion of ulcers healed within
a specified time period; percentage decrease in ulcer surface area;
rate of decrease in ulcer surface area.
Secondary outcomes
1. Health related quality of life.
2. Symptoms e.g. pain, itchiness etc.
3. Costs.
4. Adverse events e.g. pain.
Search methods for identification of studies
Search strategy for the original review andfirst update can be found
in Appendix 1 and Appendix 2 respectively.
Electronic searches
For this second update, we searched the following databases:
• Cochrane Wounds Group Specialised Register (searched 24
February 2010);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2010, Issue 1);
• Ovid MEDLINE (1950 to February Week 2 2010);
• Ovid MEDLINE In-Process & Other Non-Indexed
Citations (Searched 24 February 2010);
• Ovid EMBASE (1980 to 2010 Week 07);
• EBSCO CINAHL (1982 to 24 February 2010).
We searched The Cochrane Central Register of Controlled Trials
(CENTRAL) using the following strategy:
#1 MeSH descriptor Varicose Ulcer explode all trees
#2 MeSH descriptor Leg Ulcer explode all trees
#3 (varicoseNEXTulcer*) or (venousNEXTulcer*) or (legNEXT
ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*)
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Ultrasonic Therapy explode all trees
#6 ultrasound NEAR/5 therap*
#7 ultrason* NEAR/5 therap*
#8 (#5 OR #6 OR #7)
#9 (#4 AND #8)
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 3, Appendix 4 and
Appendix 5 respectively. The Ovid MEDLINE search was com-
bined with the Cochrane Highly Sensitive Search Strategy for
identifying randomised trials in MEDLINE: sensitivity- and pre-
cision-maximizing version (2008 revision); Ovid format (Lefebvre
2009). The EMBASE and CINAHL searches were combined with
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the trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2009). There was no restriction by language, date
or publication status.
Searching other resources
We attempted to contact researchers to obtain any unpublished
datawhen needed. Reference lists of potentially useful articles were
also searched.
Data collection and analysis
Selection of studies
For the initial version of the review, titles and abstracts of studies
identified by searches were assessed for eligibility by one review
author (KF). Full reports were obtained if, from this initial assess-
ment, they appeared to satisfy the inclusion criteria. Those rejected
were checked by another review author (NC). Full papers were
checked to identify those that were eligible for inclusion. This was
repeated independently by another review author (NC) to provide
verification. Any disagreement was resolved by discussion, and,
if necessary, by referral to a third review author for adjudication.
Details of the studies were extracted and summarised using a data
extraction sheet. If data were missing from reports, then attempts
were made to contact the study authors to obtain missing infor-
mation. Studies that were published in duplicate were included
only once. Data extraction was undertaken by one review author
and checked for accuracy by a second review author.
The same process was followed with different review authors for
the subsequent review updates, always with at least two review
authors working independently.
Data extraction and management
For this update, all original data were re-extracted by NC and
checked by a second review author (SBS).
The following data were extracted:
- country of origin and health care setting;
- eligibility criteria: baseline patient characteristics by treatment
group;
- details of the US regimen received by the intervention group plus
co-interventions;
- details of the ulcer care regimen received by the comparison
group;
- primary and secondary trial outcome(s);
- results including primary and secondary outcomes, adverse
events, numbers of withdrawals, all by treatment group.
Assessment of risk of bias in included studies
For the update of this review, two review authors independently
assessed each included study, without blinding to journal or au-
thorship, using the Cochrane Collaboration tool for assessing risk
of bias (Higgins 2009). This tool addresses six specific domains,
namely sequence generation, allocation concealment, blinding, in-
complete outcome data, selective outcome reporting and other is-
sues (e.g. extreme baseline imbalance) (see Appendix 6 for details
of criteria on which the judgements were based). Blinding and
completeness of outcome data were assessed for each outcome sep-
arately.We completed a risk of bias table for each eligible study.We
discussed any disagreement amongst all review authors to achieve
a consensus.
We presented an assessment of risk of bias using a risk of bias
summary figure (Figure 1), which presents all of the judgments
in a cross-tabulation of study by entry. This display of internal
validity indicates the weight the reader may give the results of each
study. Studies were classed as being at high risk of bias if any one
of the criteria received a “No” classification.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Dealing with missing data
High rates of withdrawal from trials are common in chronic
wounds research, and trialists have tended to deal with such pa-
tients as being lost-to-follow-up and ignored them in the analysis.
This approach clearly disrupts randomisation, and has a high po-
tential for introducing bias - largely by ignoring patients who have
failed to heal. For the main analysis we have, therefore, regarded
participants who were lost-to-follow-up (i.e. randomised but not
appearing in the analysis) as unhealed - where healingwas themain
endpoint - as this seems the most plausible outcome, however, we
have also tested this approach by conducting complete case anal-
yses alongside (see Analysis 2.3; Analysis 2.4). Application and
comparison of both these approaches was not pre-specified in the
original protocol.
Assessment of heterogeneity
Heterogeneity was tested for using the Chi² statistic, and the
amount of variation due to heterogeneity was assessed using I²
(Higgins 2003).
Data synthesis
The studies included in the review were combined by narrative
overview with meta-analysis of outcome data where appropriate,
conducted using RevMan 5 software. Relative risk with 95% con-
fidence intervals (CI) was calculated for each trial with important
dichotomous outcomes (e.g. number of ulcers healed). Continu-
ous data were presented and analysed using differences in means
with 95% CI. For this update the evidence was presented accord-
ing to US frequency (high-frequency being 1MHz and low-fre-
quency being 30kHz). We compiled two Summary of Findings
Tables using Gradeprofiler; one each for high frequency and low
frequency ultrasound. We estimated control group event rates for
patients at medium risk of healing using the average risk of healing
in the included studies; we estimated control group event rates for
patients at high risk of healing from a large, well conducted trial
that exposed participants to best practice (Iglesias 2004).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
The initial version of this review included seven studies. The first
update included the original seven plus one new study (Franek
2004), making a total of eight (Callam 1987; Dyson 1976;
Eriksson 1991; Franek 2004; Lundeberg 1990; Peschen 1997;
Roche 1984; Weichenthal 1997). For this second update we have
included two new RCTs (Dolibog 2008; Taradaj 2008), but ex-
cluded two previously included studies on the grounds that they
used quasi random allocation methods and were consequently at
substantial risk of selection bias (Dyson 1976; Roche 1984). A
total of six studies were therefore excluded from the review at
the full text stage as they were not randomised controlled trials
(Dissemond 2003; Dyson 1976; Kavros 2007b; Roche 1984; Tan
2007) or involved people with arterial rather than venous ulcers
(Kavros 2007a). We identified a further two citations to poten-
tially eligible studies which require translation and are therefore
classified as awaiting assessment (Franek 2006; Taradaj 2007) and
one study which is ongoing and expected to report late in 2010
(Nelson 2006). This update, therefore, includes a total of eight
RCTs.Most of the included studies were small; sample sizes ranged
between 24 and 108. All patients were diagnosed with venous leg
ulceration, and five trials out of eight reported the criteria bywhich
this diagnosis was made (Dolibog 2008; Eriksson 1991; Peschen
1997; Taradaj 2008; Weichenthal 1997).
Therapeutic US was compared with sham or placebo US in three
trials (Eriksson 1991; Lundeberg 1990; Peschen 1997), and in
the remaining five it was compared with standard ulcer care.
Three trials evaluated directly-applied US (Callam 1987; Eriksson
1991; Lundeberg 1990), and the other five evaluated US that
was indirectly-applied to the ulcers though water. Six trials evalu-
ated high-frequency therapeutic US (Callam 1987;Dolibog 2008;
Eriksson 1991; Franek 2004; Lundeberg 1990; Taradaj 2008),
whilst the other two evaluated low-frequency US (Peschen 1997;
Weichenthal 1997).
High frequency ultrasound
Lundeberg 1990 randomised 44 patients with venous leg ulcers
to receive US directly to the ulcer surface and surrounding tissue
(pulsed 1 MHz , 0.5 W/cm² for 10 minutes) plus standard treat-
ment, or placebo (sham) US plus standard treatment. After with-
drawals, 32 participants remained: 17 in the US group and 15 in
the placebo group. The regimen of standard treatment consisted of
cleansing with saline, application of paste, support bandages and
an exercise program. The frequency of treatment varied over the
course of the 12-week study, decreasing from three times weekly
for the first four weeks to twice weekly for the subsequent four
weeks, and then once weekly for the final four weeks. The objec-
tive outcome was the number of ulcers healed, and the percentage
of initial ulcer area present after 4, 8 and 12 weeks.
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In a similar study, Eriksson 1991 compared an US regimen of
1 MHz, 1.0 W/cm² US for 10 minutes, twice weekly for eight
weeks with shamUS. All participants received standard treatment,
consisting of paste-impregnated bandage and a self-adhesive elastic
bandage. The 38 participants were people referred from secondary
and primary health care settings; ulcer aetiology was confirmed by
means of a clinical examination and patient questionnaire. People
with an allergy to standard treatment, arterial disease, rheumatoid
arthritis, or with diabetic or traumatic ulcers were excluded from
this study. The outcomes measured were the number of ulcers
healed, and the percentage of initial ulcer area present at two-week
intervals for eight weeks.
Callam 1987 randomised 108 patients attending a physiotherapy
clinic for treatment of chronic venous ulcers to receive either US
(pulsed 1 MHz, 0.5 W/cm², 1 minute per probe head) and stan-
dard treatment, or standard treatment alone. Standard treatment
consisted of cleansing with 1% cetrimide/normal saline, applica-
tion of Arachis oil to the surrounding skin, Calaband paste ban-
dage and Lestreflex support bandage, plus standardised exercise.
Ulcer aetiology was assessed on basis of a questionnaire and clin-
ical examination, participants were excluded if they were allergic
to treatment or demonstrated arterial disease. Treatment occurred
weekly for 12 weeks. Healing was measured in terms of percentage
decrease in ulcer area, and the number of ulcers completely healed
under 12 weeks.
Franek 2004 randomised 65 people between three treatment
groups; two received different intensities of pulsed, 1 MHz US
(either 0.5 or 1 W/cm²) in a water bath with a temperature of
34°C plus standard treatment of topical agents, while the third
group received standard treatment only. Standard treatment com-
prised potassium permanganate baths, wet dressings of 0.1 copper
sulphate solution, fibrolan compresses, chloramphenicol, colistin,
gentamicin and a single layer of compression bandage. Patients
with arterial disease and diabetes were excluded. All three groups
were admitted to hospital for three weeks, which was also the to-
tal duration of follow up. Importantly, apart from the differences
in local wound treatment (above), the intervention groups were
treated in a university hospital, and the control group in another
nearby hospital resulting in a high risk of performance bias. Treat-
ment sessions occurred daily, and lasted from 5 to 10 minutes.
Degree of healing was quantified by the weekly rate of decrease in
ulcer surface area, volume and the number of ulcers completely
healed.
Dolibog 2008 randomised 70 people who had previously received
venous surgery between two trials arms, one of which received
0.5W/cm² pulsed US at 1 MHz frequency using the indirect, wa-
ter bath method (see above). Treatment continued on six days out
of every seven, for seven weeks. Co-interventions included com-
pression hosiery, saline soaked gauze to the ulcers and 1 g flavonoid
fraction daily. The control group received the compression stock-
ings, flavonoid fraction and saline soaks. The outcomes measured
were the number of ulcers completely healed, and extensive di-
mensional measurements of the ulcers, including mean ulcer area.
Taradaj 2008 conducted a four-group randomised trial with 81
participants. Groups 1 and 2 agreed to, and received, venous
surgerywhich included crossectomy, partial stripping of the greater
or lesser saphenous vein, local phlebectomy and ligation of insuf-
ficient perforators, as applicable to each patient. Participants in
Groups 3 and 4 had refused surgery. Group 1 and 3 were ran-
domised to receive US therapy, using the indirect, water bath ap-
proach, at 0.5W/cm² at 1MHz, plus compression therapy, saline-
soaked gauze to the ulcer and1gof flavonoid fractiondaily.Groups
2 and 4 received compression therapy, saline soaks and flavonoid.
US was received on six days out of every seven for seven weeks.
The outcomesmeasured included the number of ulcers completely
healed, plus extensive dimensional measurements of the ulcers,
including volume and area.
Low frequency ultrasound
Peschen 1997 placed participants’ legs in a 32° to 34 °C water
footbath and applied continuous 30 KHz, 0.1W/cm²US that was
compared with sham US procedure. Both treatment groups also
received standard treatment of hydrocolloid dressing plus com-
pression bandaging. The trial randomised 24 people attending an
outpatient clinic, each with a venous ulcer larger than 2 cm² of
at least three months’ duration. Venous aetiology was confirmed
by means of history, Doppler sonography and light-reflection-
rheography. Peoplewith gastrointestinal, liver, cardiac, or renal dis-
ease, diabetes, polyneuropathy, rheumatoid arthritis, malignancy,
or allergy to standard treatment were excluded. Treatment sessions
lasted 10 minutes and took place three times a week for 12 weeks.
The outcomes measured were number of ulcers completely healed
at 12 weeks and percentage reduction in ulcer area at the end of
the treatment and after 25 weeks.
Weichenthal 1997 employed the same indirect US regimen as
Peschen 1997. Thirty-seven people were randomised to receive
either 30 kHz of US at 0.1 W/cm² for 10 minutes from an US
applicator mounted in a footbath, plus conventional treatment,
or conventional treatment alone, which consisted of fibrinolytic
agents, antibiotics, antiseptic agents, and occlusive dressings. Par-
ticipants each had a venous ulcer of more than three months’ du-
ration, and no evidence of arterial disease or diabetes. Follow-up
was for eight weeks, with outcome measures of number of ulcers
completely healed and percentage decrease in ulcer area.
Risk of bias in included studies
We classified studies as being at high risk of bias if they were rated
“No” for any of the four key criteria (randomisation sequence
generation, allocation concealment, blinding and incomplete out-
come data addressed). Every study was deemed to be at high risk
of bias, except Eriksson 1991, which was rated unclear for every
criterion (see Figure 2; Figure 1 for a summary of the risk of bias).
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Adequacy of randomisation process
All study authors stated that the participants were randomised.
Three studies provided sufficient information to indicate that par-
ticipants were randomised according to an adequate randomisa-
tion sequence. Weichenthal 1997 used computer-generated ran-
dom numbers, Lundeberg 1990 and Callam 1987 used ran-
domised permuted blocks. The randomisation method was not
mentioned in five studies (Dolibog 2008; Eriksson 1991; Franek
2004; Peschen 1997; Taradaj 2008).
Allocation concealment
Callam 1987 used a central office to conceal allocation and was the
only included study to describe concealed allocation adequately.
Every other study was rated unclear for allocation concealment.
Blinding
No study reported what could be regarded as fully-blinded out-
come assessment. In three studies (Callam 1987; Eriksson 1991;
Lundeberg 1990), ulcer tracings were completed by unblinded
staff but the analysis (computer-aided measurement of ulcer area)
of coded tracings was undertaken by staff who were blinded to
treatment group. Whilst this probably affords some protection
against measurement bias, the accuracy of initial tracings may
have been adversely influenced by the awareness of the tracer of
the allocation group. Two trials did not provide sufficient infor-
mation for us to judge whether outcome assessment was blinded
(Dolibog 2008; Peschen 1997). Three trials clearly did not employ
any blinding of outcome assessment (Franek 2004; Taradaj 2008;
Weichenthal 1997). Since the judgement of when healing actually
occurs is, to a certain extent, subjective, we classified trials without
blinded outcome assessment as being at high risk of bias even if
this was the only criterion failure, as in the case of Callam 1987.
Incomplete outcome data
The only trial that explicitly attempted to reduce the bias associated
with incomplete outcome data was Callam 1987; five trials were
unclear (Dolibog 2008; Eriksson 1991; Franek 2004; Taradaj
2008; Weichenthal 1997), and the remaining two appeared to
have omitted non-compliant patients from their analyses, thereby
introducing a high risk of bias (Lundeberg 1990; Peschen 1997).
Other biases
The results of Franek 2004 should be viewed with extreme caution
as the treatment groups differed in important aspects of care apart
from the US treatment. The non-US group received an intensive
wound treatment regimen thatwas not given to the twoUS groups,
and, furthermore, while the patients in the two US groups were
admitted to the same hospital, the non-US group were admitted
to a completely different hospital.
Outcome measures used
There is a great deal of variation in wound healing trials in the
selection, as well as reporting of outcome measures, and very little
methodological research to validate the wound outcome measures
used. Arguably, time towound healing is themost patient-oriented
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outcome, since, even in trials of treatments for chronicwounds, the
majority do achieve healing. Survival analysis is the most appro-
priate strategy for analysing a time-to-event outcome such as time-
to-healing, with hazard ratio as the effect measure, however, this
is very rarely used. Three trials (Callam 1987; Lundeberg 1990;
Peschen 1997) used life tablemethods to compare healing rates but
did not report hazard ratios. All trials did report the proportion of
ulcers completely healed at arbitrary and varying follow-up times
(duration of follow-up ranged between three weeks (Franek 2004)
and 12 weeks (Callam 1987; Lundeberg 1990; Peschen 1997).
The remaining trials reported healing by seven or eight weeks.
None of the included trials appears to have measured the sec-
ondary outcomes of health-related quality of life, adverse events or
costs in a systematic way (certainly did not report them). Several
trials reported numbers of withdrawals due to pain or bleeding,
and mentioned some adverse events; these have been described in
narrative form alongside the trial results.
Effects of interventions
See: Summary of findings for the main comparison High
frequency US compared to no ultrasound for venous leg ulcers;
Summary of findings 2 Low frequency US compared to no
ultrasound for venous leg ulcers
For this update the results are presented separately for high and
low frequency US, though this approach was not pre-specified in
the protocol. We present the (unpooled) results of all six trials that
reported ulcer healing data at seven or eight weeks in Analysis 1.1.
Five out of the six trials reported more healing in the US-treated
groups compared with no US, although in only one of these trials
was the difference statistically significant (Callam 1987).
Three RCTs evaluated directly-applied US (all high-frequency)
(Callam 1987; Eriksson 1991; Lundeberg 1990) and five RCTs
evaluated indirectly-applied US: i.e. Dolibog 2008; Franek 2004;
and Taradaj 2007 (all high-frequency) and Peschen 1997 and
Weichenthal 1997 (low-frequency US delivered via a waterbath).
We regarded indirectly- and directly-applied US as sufficiently
similar to be analysed together. Three trials compared US therapy
with sham US (Eriksson 1991; Lundeberg 1990; Peschen 1997),
whilst five compared US therapy with standard treatment (Callam
1987; Dolibog 2008; Franek 2004; Taradaj 2007; Weichenthal
1997).
There was much heterogeneity in the nature and timing of out-
comes reported across all trials. Trialists reported a combination of
the number of ulcers healed at specified (and varied) time points,
mean change in ulcer size at varied time points, or both.
High frequency ultrasound
Six RCTs evaluated high-frequency US involving a total of 406
randomised participants (Callam 1987; Eriksson 1991; Lundeberg
1990; Dolibog 2008; Taradaj 2008; Franek 2004). The trial by
Franek 2004 reported numbers of ulcers healed,mean andmedian
change in ulcer area at 3 weeks only. Taradaj 2008 and Dolibog
2008 reported healing at 7weekswhilst the trials byEriksson1991;
Callam1987 andLundeberg 1990 reported healing at eight weeks.
Callam 1987 and Lundeberg 1990 also reported ulcers healed at
12 weeks.We pooled the results of these six RCTs for the outcome
of complete ulcer healing at any time point (I2=0) using a random
effects model. There was no statistically significant difference in
the relative risk of healing between US treated patients and those
not receiving US (RR 1.34, 95% CI 0.99 to 1.80) (Analysis 2.1).
Ulcers healed at 3 weeks
One trial (Franek 2004) reported outcomes at three weeks only;
this is an extremely short duration of follow up, during which one
would expect to see very few ulcers completely healing.
The results of Franek 2004 should be viewed with extreme caution
for several reasons; apart from the paucity of endpoint data due to
the brief follow up the trial was confounded and likely to be sub-
ject to important performance bias - we have included it here since
we did not pre-specify that we would exclude trials where US was
not the only systematic difference in treatments. The trial involved
three treatment arms: twoUS arms (1W/cm² and 0.5W/cm²) and
a control arm with no US. However, the control group received
co-interventions (in the form of local wound treatments) that were
not received by the US patients (potassium permanganate and wet
dressings of 0.1 copper sulphate solution plus compresses of fi-
brolan, chloramphenicol, colistin, gentamicin), and, furthermore,
they were treated in a different hospital. At three weeks complete
healing had occurred in 1/22 (4.5%) of the group receiving 1 W/
cm² US, 3/21 (14.3%) of the group receiving 0.5W/cm² US, and
1/22 (4.5%) of people receiving no US. For the purposes of the
main analysis we have pooled both US arms and compared them
with no US. This preserves randomisation but results in unequally
sized groups. There was no statistically significant difference in
the proportion of ulcers healed with US compared with no US at
three weeks (RR 2.05, 95% CI 0.24 to 17.23) (Analysis 2.2).
There was no reporting of secondary outcomes (health-related
quality of life (HRQoL), pain, adverse events or costs) in this trial.
Healing at 7 - 8 weeks
Callam 1987: there was a statistically significant increase in the
risk of healing associated with US over standard therapy alone at
eight weeks (eight week data read from the graph in the published
paper). Twenty-three out of 52 participants randomised to US
healed by eight weeks (44%), compared with 14 out of 56 (25%)
randomised to standard treatment alone. The relative risk (RR)
for healing with US compared with no US was 1.77, 95% CI 1.02
to 3.06 (Analysis 1.1).
Eriksson 1991: there was no statistically significant difference in
outcomes between US and sham at 8 weeks. The ulcers of 6/
19 participants (32%) randomised to the US group had healed
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by eight weeks compared with 4/19 (21%) in the sham group
(RR 1.50, 95% CI 0.50 to 4.48) (Analysis 1.1). Thirteen out of
38 participants randomised (34%) withdrew from this trial. The
mean percentage of initial ulcer area remaining at 8 weeks was
42% (SD 9%) in the US group and 48% (SD 13%) in the sham
group (no statistically significant difference).
Lundeberg 1990: there was no statistically significant difference
between ultrasound and sham ultrasound in the proportion of
participants whose ulcers healed completely. At eight weeks 5/22
(23%) participants healed with US compared with 3/22 (14%) in
the sham group (RR 1.67, 95% CI 0.45 to 6.14 (Analysis 1.1).
Themean percentage of initial ulcer area remaining at 8 weeks was
47% (SD 8%) in the US group compared with 53% (SD 10%)
in the sham group.
Taradaj 2008: for the purposes of the main analysis we pooled
the results for both US arms (surgery plus no surgery) and both
control arms (surgery plus no surgery). At seven weeks there was
no statistically significant difference in the proportion of ulcers
healed between those receiving US and those who did not (RR
1.30, 95% CI 0.62 to 2.74) (Analysis 1.1). The mean reduction
in ulcer area at 7 weeks was also reported but without variance
data so could not be plotted here. The authors reported mean
reduction in ulcer area in the surgical patients of 58.21% with US
compared with 58.36% (no US); and for the non-surgery patients
the reduction was 56.67% with US and 36.09% without US.
Dolibog 2008: at seven weeks 10 out of 33 participants in the US
had completely healed compared with 12 out of 37 in the control
group (no statistically significant difference, RR 0.93, 95% CI
0.47 to 1.87) (Analysis 1.1). Dolibog 2008 also reported the mean
wound area at baseline and 7 weeks. Mean ulcer area at baseline
in the US group was 24.27cm2 (SD 17.12) which reduced to
13.15cm2 (SD 11.55). Mean baseline area in the control group
was 24.92cm2 (SD16.19) which reduced to 13.12cm2 (SD14.57)
(no evidence of a difference).
We regarded it as appropriate to pool the results for Callam 1987;
Eriksson 1991; Lundeberg 1990; Taradaj 2008 and Dolibog 2008
for seven to eight weeks’ follow-up as there appeared to be no
statistical heterogeneity (I²=0).We regarded those randomised but
lost to follow up as unhealed in this analysis (i.e., they appeared
in the denominator). After seven to eight weeks of US treatment,
there was a statistically significant increase in the proportion of
ulcers healed with US compared with no US (pooled RR 1.40,
95% CI 1.00 to 1.96; I²=0, fixed-effect) (Analysis 2.3). When
this analysis is undertaken using a random effects model (possibly
the more appropriate approach given the differences between the
trials), this difference is no longer statistically significant (RR 1.4,
95% CI 0.99 to 1.96, not shown). Similarly this difference is
no longer statistically significant (RR 1.36, 95% CI 0.98 to 1.88
Analysis 2.3 ) when a complete case analysis is undertaken.
Healing at 12 weeks
Callam 1987 also reported healing after 12 weeks of treatment
at which point there was no statistically significant difference be-
tween US plus standard care and standard care alone (RR 1.58,
95% CI 0.97 to 2.58) (Analysis 2.4). Callam 1987 also reported
percentage decrease in ulcer area over time and mean residual ulcer
area remaining at 12 weeks as a% of baseline however did not pro-
vide any variance data around themean estimates and this analysis
is problematic since 37 participants had healed completely. They
reported that at 12 weeks 9% of initial ulcer area remained in the
US group compared with 27% in the standard care group and that
this difference was statistically significant in favour of US.
At 12 weeks’ follow up, Lundeberg 1990 reported that 10/22
(45%) ulcers healed with US compared with 8/22 (36%) in the
sham group (RR 1.25, 95% CI 0.61 to 2.56, no statistically sig-
nificant difference Analysis 2.4). Lundeberg 1990 also reported
percentage initial ulcer remaining at 12 weeks (39%, SD 5% with
US and 43%, SD 6% with sham US, no statistically significant
difference).
Pooling the two studies found no statistically significant difference
in the proportions of participants whose ulcers had healed at 12
weeks with US compared with no US (RR 1.47, 95% CI 0.99 to
2.20, fixed effect I²=0) (Analysis 2.4); however, this comparison
is statistically underpowered for detecting a clinically important
treatment effect, with only 152 participants randomised. The re-
sult did not change when a random effects model was applied.
Both trials were regarded as being at high risk of bias for healing
outcomes.
Secondary outcomes
In the Callam 1987 trial a total of 26 out of 108 randomised
participants withdrew (24%), leaving 76% of those randomised
to provide outcome data. Proportions and reasons for withdrawal
were similar across the two treatment groups. Eleven out of 52
randomised (21%) withdrew from the US group for reasons of
allergy (four), pain (four), death (two), and withdrawn consent
(two). Fifteen out of 56 (27%) withdrew from the standard care
group for reasons of allergy (six), pain (three), deterioration (two),
withdrawal of consent (three), and newly-diagnosed arterial dis-
ease (one).
In the Eriksson 1991 trial 7/19 (37%) participants randomised
withdrew from the US group (three for “allergy”, two for pain,
and two withdrew consent) compared with 6/19 (32%) from the
control group (two for “allergy”, one for pain, three withdrew
consent).
In the Lundeberg 1990 trial, 5/22 participants (23%) randomised
to US withdrew (two for “allergy”, one for pain, two withdrew
consent) compared with seven out of 22 (32%) from the sham
group (three for “allergy”, one for pain, three withdrew consent).
Dolibog 2008; Franek 2004 and Taradaj 2008 did not report any
withdrawals or adverse events.
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Low-frequency ultrasound
Two RCTs evaluated indirectly-applied, low-frequency US. Both
Peschen 1997 and Weichenthal 1997 applied 30 kHz, 0.1W/cm²
three times a week via a water bath. These trials reported healing
outcomes at different time points (12 weeks in Peschen 1997 and
eight weeks in Weichenthal 1997).
Healing at 8 - 12 weeks
Peschen 1997: there was no statistically significant difference be-
tween US and no US in the proportion of participants whose ul-
cers healed completely over the 12 weeks of the trial (2/12 ulcers
healed in the US group compared with 0/12 ulcers in the sham
group; RR 5.00, 95% CI 0.27 to 94.34) (Analysis 3.1).
Weichenthal 1997: by eight weeks one ulcer had healed completely
in the US group compared with none in the standard therapy
group (RR 2.85, 95% CI 0.12 to 65.74) (Analysis 3.1). This
difference was not statistically significant.
We pooled these two studies for the outcome of healing at 8 -
12 weeks (I²=0), using a fixed effect model (Analysis 3.1). There
was no statistically significant difference in the risk of healing
associated with low frequency US applied twice a week (RR 3.91,
95% CI 0.47 to 32.85). This result did not change appreciably
when a random effects model was applied (RR 3.85, 95% CI
0.45 to 32.84, not shown) however as there were only three ulcers
healed across these two trials this comparison is underpowered and
a treatment effect cannot be excluded.
Secondary outcomes
Weichenthal 1997: Microbleeding around the ulcer occurred in
5/12 ulcers in the US group compared with none in the sham US
group. Patients’ experiences of pain were reported, however, this
does not appear to have been systematically measured. Pain was
reported as follows: US group: one patient reported no change in
baseline pain, eight patients complained of pain “prior to treat-
ment”; pain was no longer reported by any patients starting in
week four. Sham group: one patient reported no change in baseline
pain; 10 patients complained of pain at various time points.There
was no reporting of HRQoL or costs.
Peschen 1997: treatment-related adverse events were only reported
for patients in the US group. Eleven out of 19 patients in the US
group felt no pain or mild pain on fewer than three treatment
occasions; 7/19 US patients reported pain on more than two occa-
sions, but severe pain on fewer than three treatment occasions; 1/
19 US patients reported severe pain on more than two occasions.
Twelve out of 19 US patients experienced erythema on more than
two occasions. There was no reporting of HRQoL or costs.
Sensitivity analyses
Where the numbers randomised differed from the numbers anal-
ysed, we undertook the primary analysis using the numbers ran-
domised as the denominator (i.e. assuming losses to follow-up
were unhealed). We then examined the impact of this decision in
a sensitivity analysis where we analysed complete cases only.
High-frequency US
Looking at the trials which evaluated high-frequency US and re-
ported outcomes at 7 - 8 weeks (Callam 1987; Eriksson 1991;
Lundeberg 1990; Dolibog 2008; Taradaj 2008) (Analysis 2.3), we
can see that the result of complete case analysis (RR for healing
with US 1.36, 95% CI 0.98 to 1.88) is not substantively differ-
ent from the result when losses are regarded as unhealed (RR for
healing with US 1.4, 95% CI 1.00 to 1.96). At 12 weeks follow
up, the RR for healing with US compared with no US using a
complete case analysis is 1.35, 95% CI 0.94 to 1.93; whilst when
regarding losses as unhealed the RR is 1.47, 95% CI 0.99 to 2.20
(Analysis 2.4).
Low-frequency US
In the trial of Peschen 1997, two participants dropped out of
the non-US group for non-compliance; there was no appreciable
difference in the result whether complete case analysis was used
or whether losses were regarded as unhealed (RR for ulcer healing
at 12 weeks for US compared with no US when losses regarded
as unhealed is 5.00, 95% CI 0.27 to 94.34; RR for ulcer healing
at 12 weeks using complete case analysis is 4.23, 95% CI 0.23 to
79.10, not shown).
Summary of Findings Table
We have included Summary of Findings tables (Summary of
findings for the main comparison; Summary of findings 2) in this
update, which give a concise overview and synthesis of the volume
and quality of the evidence. The Summary of Findings tables (one
each for high and low frequency US) confirm our conclusion that
the quality of evidence is very low and on balance there is no strong
evidence of a benefit of US on venous ulcer healing.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Low frequency US compared to no ultrasound for venous leg ulcers
Patient or population: patients with venous leg ulcers
Settings: any
Intervention: Low frequency US
Comparison: no ultrasound
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
no ultrasound Low frequency US
Proportion ulcers com-
pletely healed at 8 - 12
weeks
Study population1 RR 3.91
(0.47 to 32.85)
61
(2 studies)
⊕©©©
very low2,3
0 per 100 0 per 100
(0 to 0)
High risk population1
30 per 100 100 per 100
(14 to 100)
HRQoL - not reported See comment See comment Not estimable - See comment Venous leg ulcers have a
large, negative impact on
quality of life however no
study reported this
Pain - not reported See comment See comment Not estimable - See comment Venous leg ulcers can
be extremely painful and
treatments can increase
the level of pain or dis-
comfort. No study mea-
sured pain using ac-
cepted approaches15
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 With best practice care (high compression bandaging), a baseline risk of healing at 10 weeks (midpoint of 8 and 12 weeks) would be
approximately 30% (Iglesias et al).
2 Both studies at unclear or high risk of bias.
3 Only 3 participants in the two trials reached the endpoint (complete ulcer healing). All 3 participants were in the ultrasound arms of the
trials.
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D I S C U S S I O N
This systematic review has identified no strong evidence that ther-
apeutic US speeds the healing of venous leg ulcers, however, all
the trials included were too small to detect clinically important
treatment effects, and even meta-analysis of these small trials will
not provide adequate statistical power. Furthermore, most of the
evidence was at high risk of bias due to common failings in trial
conduct, most notably the lack of blinded outcome assessment
and failure to deal with incomplete outcome data appropriately.
Poor reporting was also an issue, and in all but one case it was
impossible to discern whether the randomisation was adequately
concealed.
Whilst there was some evidence that high-frequency (1 MHz)
therapeutic US (used as infrequently as once a week) may increase
the proportion of ulcers healed at eight weeks, this effect seemed to
have disappeared by 12 weeks, and the risk of bias means that this
is extremely weak evidence and insufficient to act upon clinically.
There was no evidence at all of a treatment effect associated with
low frequency US; though again low statistical power and risk of
bias means we cannot entirely rule out an effect.
None of the trials identifiedmeasured health related quality of life.
Perhaps more surprisingly, none appears to have measured pain in
a systematic, validated way (e.g. by using a visual analogue scale)
nor collected adverse event data systematically - these failings must
be reversed in future studies.
Future wounds trials should adhere to the expected international
standards of RCTs in other areas of health care. This would include
concealed allocation; blinding (or at least blinded adjudication of
outcome assessment); more complete ascertainment of endpoints
with intention-to-treat analysis. In future trials, where participants
are withdrawn from trial treatments, as frequently occurs, they
should not be withdrawn from the trial (unless of course they
withdraw consent); rather they should be followed-up as planned,
and their outcomes analysed by intention-to-treat, since to do
otherwise introduces serious bias. Furthermore, ideally, trialists
should follow-up participants for at least six months in order to
observe healing, and report time to healing as the primary outcome
(since this is the outcome that is usually most appropriate and
likely to matter themost to patients). More sophisticated methods
of survival analysis, such as Cox regression, should then be used.
There have been previous systematic reviews of US for wound
healing (e.g. Johannsen 2002), which concluded that whilst the
evidence was weak, US appeared to be effective. The Johannsen
2002 review included six trials, two of which were excluded from
this review (Roche 1984 and Dyson 1976) as they are not RCTs.
We have identified and included four further trials and in doing
so, we have weakened the evidence in support of therapeutic US
as a treatment for venous ulcers.
In summary, we have found no strong evidence to suggest that
therapeutic US increases the healing of venous leg ulcers.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence to support the routine use of therapeutic
ultrasound (US) as a treatment for venous leg ulcers. The evidence
that exists is of low quality and volume, and a beneficial effect
cannot be ruled out.
Implications for research
An adequately-powered randomised controlled trial is required to
determine whether therapeutic ultrasound (US) does speed the
healing of venous ulcers. Such a trial might either be explanatory,
and compare US with sham US, or probably more usefully, be
pragmatic and attempt to establish whetherUS is likely to be effec-
tive if used in clinical practice. This would probably mean evaluat-
ing anUS regimen that is feasible, and does not require hospital ad-
mission or multiple treatments per week. In a pragmatic trial, the
comparisons would be the best available standard treatment plus
US, compared with standard treatment alone. Outcomes should
include time to ulcer healing, quality of life (including pain), ad-
verse events and costs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Callam 1987
Methods Patients with chronic leg ulcers who were attending physiotherapy departments in Scot-
land, UK, individually randomised to receive US or standard care
Participants 108 patients attending participating physiotherapy clinics. Exclusion criteria included
allergy to standard treatments, peripheral vascular disease.
US group: 52;
Standard treatment group: 56.
Interventions US group: once weekly pulsed, direct US 0.5Watt per cm² at a frequency of 1 MHz, ap-
plied directly to the tissue surrounding the ulcer for 12 weeks or until healing (whichever
occurred first) plus standard treatment (see below).
Standard treatment group: standard regimen of 1% cetrimide in normal saline, followed
by Arachis oil to the skin (no massage), a paste bandage (Calaband), a Lestreflex support
bandage and an exercise instruction sheet
Outcomes The number of ulcers completely healed at 12 weeks (losses considered as treatment
failures).
The mean % of initial ulcer area remaining at 12 weeks.
Withdrawals by treatment group with reasons.
Notes Ulcers were traced; tracers were not blind to treatment group, but analysis of tracings
was blinded. Withdrawn patients were censored at the point of withdrawal except for
those who were withdrawn due to deterioration, who were regarded as unhealed at 12
weeks.
NB the original Lancet paper report of this trial stated that the US frequency was 1 mHz.
We contacted Mr Callam, the Principal Investigator, in November 2009. He confirmed
that the frequency was 1 MHz (bringing the trial into line with most of the others).
Duration of follow-up: 12 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Patients were randomised into a control
group... and a treatment group...”
Allocation concealment? Low risk “Randomisation was made through a cen-
tral office and was based on the use of
randomised permuted blocks, with strati-
fication to ensure that appropriate balance
between the treatment groups was main-
tained at each centre”
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Callam 1987 (Continued)
Blinding?
Ulcer healing
High risk Participants and personnel not blinded.
Outcome assessors: tracings of the ulcer
circumference were completed by people
who were not blind to treatment group,
however, analysis of the tracings (calcula-
tion of percentage area ulcer remaining)
was blinded to treatment group: “The trac-
ings were identified only by a code number
to exclude observer bias...”
Incomplete outcome data addressed?
Ulcer healing
Low risk Similar numbers withdrew from treatment
groups for similar reasons; treated as cen-
sored except for the twopatients in the non-
US group who withdrew due to deterio-
ration and were regarded as unhealed by
study authors
Free of selective reporting? Unclear risk Expected outcomes reported, though did
not request a study protocol
Free of other bias? Low risk
Dolibog 2008
Methods Patients who had undergone venous surgery were randomised to receiveUS plus standard
care or standard care alone
Participants 70 post venous-surgery patients whose venous disease was diagnosed by Duplex scan (to
rule out arterial disease and locate the venous insufficiency). 33 participants received US
plus standard care and 37 received standard care alone. Excluded people with diabetes,
and rheumatoid arthritis
Interventions US group: US via a water bath at 0.5W/cm²; 1 MHz frequency, US probe 10cm² placed
2 cm above ulcer. An ulcer of 5 cm² or less had 5 min treatment with one minute extra
of treatment per 1 cm² over the 5cm2 area. Treatment daily for six days per week for
seven weeks. Between treatments ulcers were covered with saline-soaked gauze, received
compression and 1 g flavonoid fraction daily. US commenced 5 days after surgery.
Standard care group: saline soaks, compression, 1 g flavonoid fraction daily
Outcomes Proportion of ulcers completely healed.
Notes Ulcers were observed for complete healing and measured for area, volume and a range
of dimensions using planimetry.
Duration of follow-up: seven weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
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Dolibog 2008 (Continued)
Adequate sequence generation? Unclear risk “70 patients ... were included and allocated
into two comparative groups”. “A prospec-
tive, randomised, controlled clinical trial
was conducted...”
Allocation concealment? Unclear risk Not mentioned. See above.
Blinding?
Ulcer healing
High risk Participants: not blinded, since they did not
receive sham US.
Personnel: unclear, but presumably not
blinded since not sham controlled.
Outcome assessors: unclear. “Treatment
progress was evaluated by observing the
number of completely healed ulcers, and
measuring the area ... by planimetry...”.
Incomplete outcome data addressed?
Ulcer healing
Unclear risk Final numbers not stated; complete follow-
up implied.
Eriksson 1991
Methods Randomised trial comparing US plus standard care with sham US plus standard care
Participants Patients with venous leg ulcers referred from departments of internal medicine and
surgery, and primary care providers. People were excluded if they were allergic to the
standard treatment, or if they had evidence of peripheral arterial disease; rheumatoid
arthritis; diabetic ulcers; or traumatic venous ulcers
Interventions US group: US 1 W/cm² at 1 MHz, for 10 min twice a week for 8 weeks, plus standard
treatment (n = 19).
ShamUS group: standard treatment plus shamUS as above but with no output. Standard
care comprised cleansing with saline; paste bandage, support bandage plus exercise advice
(n = 19)
Outcomes Number of ulcers known to be completely healed at 8 weeks (of those randomised).
% ulcer area healed at 8 weeks (SD).
Withdrawals with reasons, and by group.
Notes Duration of follow-up: 8 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “... patients were randomly assigned to ei-
ther a control group ... or a treatment
group...”
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Eriksson 1991 (Continued)
Allocation concealment? Unclear risk See above.
Blinding?
Ulcer healing
Unclear risk Participants: this is a “placebo” (sham) US
controlled trial, therefore, it is implied that
the participants did not know their alloca-
tion.
Personnel: unclear (they may have been re-
sponsible for setting the ultrasound ma-
chine to zero).
Outcome assessors: unclear whether those
responsible for taking ulcer tracings were
blinded. Those responsible for analysing
the tracings were blinded: “At the end of
the 8 week study all tracings were analysed
using a computer graphics program to cal-
culate the areas of each ulcer...The tracings
were identified by code numbers to exclude
observer bias.”
Incomplete outcome data addressed?
Ulcer healing
Unclear risk 38 people randomised; 13 withdrew. Not
clear how these were handled: “The cumu-
lative percentage of healed ulcers in the two
groups was compared by the use of life ta-
ble methods” (censoring not mentioned).
In the Results section: “If analysed by in-
tention to treat there were similar non-sig-
nificant findings between the groups”
Franek 2004
Methods Randomised trial comparing two US densities (0.5 W/cm² and 1 W/cm²) with no US
and pharmacotherapy
Participants 65 patients with signs of venous disease and anABPI > 1.0, were admitted to dermatology
departments. People were excluded if they had diabetes mellitus or advanced sclerosis.
US group 1 (1 W/cm²): n = 22;
US group 2 (0.5 W/cm²): n = 21;
Pharmacotherapy group: n = 22.
Mean (median) baseline area (cm²):
US group 1: 15.62 (12.51);
US group 2: 15.57 (6.71);
Pharmacotherapy group: 23.74 (11.72).
The authors did not publish the SD or SE around the mean.
Interventions US group 1: pulsed 1 MHz, 1 W/cm² in a water bath with a temperature of 34 °C plus
standard treatment of topical wet dressings of isotonic salt solution and compression
therapy. Patients were admitted to the Dermatology Clinic of the Silesian Medical Uni-
versity in Katowice.
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Franek 2004 (Continued)
US group 2: pulsed 1 MHz, 0.5 W/cm² in a water bath with a temperature of 34 °C
plus standard treatment of topical wet dressings of isotonic salt solution and compres-
sion therapy. Patients were admitted to the Dermatology Clinic of the Silesian Medical
University in Katowice.
Pharmacotherapy group: topical pharmacotherapy including potassium permanganate
local baths, wet dressing of 0.1 copper sulphate solution, compresses of fibrolan, chlo-
ramphenicol, colistin, gentamicin plus compressive therapy. Patients were hospitalised
in the Dermatology Department of Hospital No. 2 in Zabrze
These 3 treatment groups differed systematically not only in the US treatment but the
pharmacotherapy received by the Pharmacotherapy group and its place of treatment
(different from that of the US groups)
Outcomes Number of ulcers completely healed at 3 weeks.
Average weekly rate of ulcer area reduction (% per week).
Notes No withdrawals reported.
“Planimetric measurements of homothetic, congruent projections of the ulcerated areas
using a digitising tablet. Ulcer depth measured ...with a precision built mechanical
micrometer...”
Duration of follow-up: 3 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “A total of 65 patients with venous ulcers
were randomly divided into three groups..
.”
Allocation concealment? Unclear risk See above.
Blinding?
Ulcer healing
High risk Participants: no (no sham US).
Personnel: no; the control patients were
treated in a different hospital.
Outcome assessors: no: “To check how the
ulcers healed we measured the longest di-
mensions ... and thewidest dimensions per-
pendicular to the former ... measurements
were takenbefore the treatment, everyweek
during treatment and upon completion...”
Incomplete outcome data addressed?
Ulcer healing
Unclear risk Complete follow-up implied but not
stated. No mention of ITT
Free of other bias? High risk Major performance bias. Control grouppa-
tients (Pharmacotherapy group) received
topical ulcer treatments that were not re-
ceived by the US patients, and they were
admitted to a different hospital
25Therapeutic ultrasound for venous leg ulcers (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lundeberg 1990
Methods An RCT of directly-applied, high-frequency US in 44 leg ulcer patients compared with
sham US
Participants 44 patients with venous leg ulcers referred from departments of internal medicine,
surgery, and primary care. Exclusion criteria: peripheral vascular disease, rheumatoid
arthritis, diabetes mellitus, or traumatic venous ulcer.
US group: n = 22;
Sham US group: n = 22.
Interventions US group: US 0.5 W/cm², at 1 MHz for 10 min. US was applied to the ulcer and
surrounding tissue. Treatment frequency: 3 times a week for 4 weeks, twice a week for 4
weeks, and once weekly for 4 weeks, unless healing had occurred. Patients also received
standard treatment (see below).
ShamUS group: shamUS plus standard treatment of ulcer cleansed with saline, applica-
tion of paste bandage, support bandage and advice on exercise from a standard instruc-
tion sheet
Outcomes Number of ulcers completely healed at 12 weeks.
Mean % of initial ulcer area remaining at 12 weeks.
Withdrawals by group, with reasons.
Notes Duration of follow-up: 12 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The patients were randomly assigned...
The distribution of the patients was based
on the use of randomised permuted blocks”
Allocation concealment? Unclear risk Not mentioned.
Blinding?
Ulcer healing
Unclear risk Participants: yes (sham compared with ac-
tive).
Personnel: unclear whether they were re-
sponsible for setting the ultrasound ma-
chine to zero
Outcome assessors: unclear whether person
taking the ulcer tracing was aware of al-
location. Person analysing the tracing was
blinded: “At the end of the 12 week study
all tracings were analysed using a computer
graphics program to calculate the areas of
each ulcer... tracingswere identified by code
numbers to exclude observer bias”
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Lundeberg 1990 (Continued)
Incomplete outcome data addressed?
Ulcer healing
High risk 44 participants were randomised; 12 with-
drew (evenly distributed between groups
and for similar reasons). “Patients refused
to continue or withdrew from the study
for any of the following reasons: allergy
to treatment; excessive pain; intervening
illness...”. The analysis was by “life table
methods” but it is not clear if withdrawn
patients were censored; in the results: “The
lack of differencewas alsomaintainedwhen
taking withdrawals into consideration. If
analysed by intention to treat there were
similar non-significant findings...” suggest-
ing not
Peschen 1997
Methods People attending an outpatients’ clinic were randomised to receive either US (indirect
method) plus standard treatment or sham US plus standard treatment
Participants 24 patients attending outpatient clinic, with venous leg ulcer of minimum area 2 cm²,
and minimum duration of 3 months. Clinical diagnosis of venous disease confirmed by
history, Doppler US, light reflection rheography, ABPI ≥ 0.8. Excluded people with ar-
terial disease, liver disease, cardiac or renal insufficiency, haemorrhagic gastroduodenitis,
colitis, leukaemia, diabetes, rheumatoid arthritis, treatment allergy.
US group: n= 12;
Sham US group: n= 12.
Mean ulcer area (cm²) (SD):
US group: 15.67 (19.91);
Sham US group: 19.94 (17.11).
Mean ulcer duration (SD) (months):
US group: 5.5 (3.2);
Sham US group: 4.5 (1.1).
Interventions US group:US 30 kHz, at 0.1 W/cm² for 10 min 3 times a week plus standard therapy
(comprised hydrocolloid dressings, “strong” compression therapy). TheUSwas delivered
by placing legs in a footbath of water at 32-34 °C filled to 10 cm above the ulcer. The
US probe was immersed in the bath 5 cm from the ulcer. Continuous US given for 10
min.
Sham US group: sham US plus standard therapy.
Outcomes The ulcer was measured using planimetry at 2, 4, 6, 8, 10, 12 weeks. The initial ulcer
radius was calculated from the initial area and thereafter the daily ulcer radius reduction
calculated at each time. Photographs were taken at the same time points.
Ulcers completely healed at 12 weeks.
Mean % decrease in ulcer area at 12 weeks.
Adverse events: micro bleeding and pain around the ulcer.
Withdrawals by group and with reasons.
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Peschen 1997 (Continued)
Notes No variance data supplied for continuous outcomes.
Duration of follow-up: 12 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were randomised in parallel
groups ...”.
Allocation concealment? Unclear risk See above; no further information.
Blinding?
Ulcer healing
Unclear risk Participants: yes, sham controlled.
Personnel: almost certainly not: “The same
procedure was selected for the placebo
treatment, but noultrasoundwas generated
during the 10 min footbath”.
Outcome assessors: unclear: “the ulcer area
was measured using planimetry ... prior to
treatment and after 2, 4, 6, 8, 10 and 12
weeks of therapy”
Incomplete outcome data addressed?
Ulcer healing
High risk Two patients (both control group) were
withdrawn due to “non-compliance”
Taradaj 2008
Methods Patients assessed as having venous disease by assessment of symptoms and Duplex scan-
ning, to rule out arterial disease, were offered venous surgery. Surgery included, as ap-
propriate to each patient, crossectomy, partial stripping of the greater or lesser saphenous
veins, local phlebectomy and ligation of insufficient perforators. Post surgical patients
were randomised to receive US (indirect, water-bath method) or standard care. Patients
who refused surgery were also randomised to US or standard care
Participants Duplex scanning ruled out arterial disease. All patients had symptoms of chronic venous
insufficiency
Baseline characteristics:
Mean duration of ulcer (months) (SD):
Group 1: 32.04 (22.12) n = 21;
Group 2: 32.89 (20.89) n = 20;
Group 3: 30.99 (20.09) n = 20;
Group 4: 30.87 (20.12) n = 20.
Mean baseline area (cm²) (SD):
Group 1: 18.66 (10.22);
Group 2: 18.02 (10.72);
Group 3: 17.07 (10.42);
Group 4: 18.06 (11.09).
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Taradaj 2008 (Continued)
Interventions Group 1 (n = 21): surgery plus US, compression stockings (Sigvaris, 30-40 mmHg at
ankle), drug therapy.
Group 2 (n = 20): surgery plus compression and drug therapy.
Group 3 (n = 20): US compression and drug therapy.
Group 4 (n = 20): compression and drug therapy.
Group 1 compared with Group 2
Group 3 compared with Group 4
US 0.5W/cm² pulsed; impulse 2 mS, interval 8 mS. Frequency 1 MHz. Performed in a
bath of water with temp 34 °C. Probe head 10 cm² placed 2 cm above ulcer. An ulcer of
5 cm² or less had 5 min treatment. 1 min more treatment for each 1 cm² greater than
this size. Treatment daily for 6 days/week for 7 weeks.
Drug therapy was flavonoid (450 mg diosmin, 50 mg hesperidin), twice daily.
Ulcers covered by saline soaks. Dressings changed once daily only in clinic
Outcomes Treatment progress evaluated by observation of number of healed ulcers, measuring area
by planimetry by projecting image onto transparency paper using a digitising pallet.
Measurements of area and volume before at baseline, treatment each week
Notes Duration of follow-up 7 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “In this randomised controlled clinical
trial...”. Method of randomisation not
stated
Allocation concealment? Unclear risk “Eighty one patients with venous leg ul-
cers were included...Forty one individuals
- who agreed on surgical operation ... were
ultimately allocated into two comparative
groups 1 and 2. Other individuals - who
did not agree on surgical procedure - were
ultimately allocated into two comparative
groups 3 and 4...”
Blinding?
Ulcer healing
High risk Participants: no since not sham controlled.
Personnel: no, see above.
Outcome assessors: almost certainly not:
“Treatment progress was evaluated by ob-
servation of the number of completely
healed ulcers, andmeasuring the area of the
ulceration by planimetry of congruent pro-
jections of these wounds onto transparency
paper using a digitizing pallet...Measure-
ments of area and volume were performed
one each person before and after therapy...
”
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Taradaj 2008 (Continued)
Incomplete outcome data addressed?
Ulcer healing
Unclear risk Not mentioned. Withdrawals not men-
tioned (100% follow up implied but not
stated)
Weichenthal 1997
Methods Patients admitted to an outpatients clinic for chronic leg ulceration randomised between
0.1 W/cm² US via the indirect (water-bath) method plus conventional therapy or con-
ventional therapy alone
Participants 38 patients with chronic venous leg ulceration of minimum duration of 3 months plus
evidence of incompetent perforating or superficial veins
US group:n =19;
Conventional therapy group: n = 18.
Interventions US group: 30 kHz of US, intensity 100 mW/cm² for 10 min, plus conventional therapy.
Conventional therapy group: conventional therapy of fibrinolytic agents, antibiotics, or
other antiseptic agents, “generally compression therapy performedwith elastic bandages”
Outcomes Number of ulcers healed at eight weeks.
Mean % of initial ulcer area present at 8 weeks.
Withdrawals by group and with reasons.
Adverse events reported as pain and erythema (and reported for US group only)
Notes Duration of follow-up: 8 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Each patient was randomly assigned to re-
ceive...”. “Randomisation was performed
with sequential treatment cards which la-
belled the patient as either control or treat-
ment. The cards were produced with a
computer random number generator, pre-
serving balance for each group”
Allocation concealment? Unclear risk See above.
Blinding?
Ulcer healing
High risk Participants: no since not sham controlled.
Personnel: see above.
Outcome assessors: highly unlikely: “After
each treatment, local findings and side ef-
fects of the conventional or of the ultra-
sound treatmentwere recorded...The ulcer-
ated area was measured by planimetry after
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Weichenthal 1997 (Continued)
3 and 8 weeks...”
Incomplete outcome data addressed?
Ulcer healing
Unclear risk 1 ineligible patient excluded from the anal-
ysis: “Within the control group only 18
patients were evaluated for the study end-
points because at the end of the study
evidence of arterial vascular disease was
present in one patient, who was therefore
excluded from the evaluation.” Otherwise
complete follow up and analysis by ITT
implied, but not stated
Abbreviations
> = greater than
≥ = greater than or equal to
ITT = intention-to-treat analysis
min = minute(s)
n = number of participants in group(s)
RCT = randomised controlled trial
SD = standard deviation
US = ultrasound
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dissemond 2003 Not a trial.
Dyson 1976 Not a randomised trial.
Kavros 2007a Trial involved predominantly people with ulcers secondary to critical limb ischaemia
Kavros 2007b Trial was an open-label, non-randomised, baseline-controlled clinical case series
Roche 1984 Not a randomised trial.
Tan 2007 Non-controlled pilot study.
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Characteristics of studies awaiting assessment [ordered by study ID]
Franek 2006
Methods
Participants
Interventions
Outcomes
Notes In Polish, awaiting translation.
Taradaj 2007
Methods
Participants
Interventions Comparison of sonotherapy with compression therapy.
Outcomes
Notes Paper published in Polish; awaiting translation.
Characteristics of ongoing studies [ordered by study ID]
Nelson 2006
Trial name or title Multicentre randomised controlled trial comparing the clinical effectiveness of weekly US combined with
standard care in the treatment of ’hard-to-heal’ venous leg ulcers
Methods RCT
Participants People with chronic venous leg ulcers.
Interventions Directly-applied, high-frequency US delivered once per week plus standard care compared with standard care
alone
Outcomes Time to ulcer healing, quality of life, adverse events, costs
Starting date 2005
Contact information Dr Jude Watson, York Trials Unit, Department of Health Sciences, University of York, UK
Notes Likely to be published late 2010.
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D A T A A N D A N A L Y S E S
Comparison 1. Ultrasound (any frequency) vs no ultrasound
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of ulcers healed at 7
or 8 weeks
6 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. High frequency US vs no ultrasound
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of ulcers completely
healed during study follow up
(varying durations of follow
up)
6 406 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.99, 1.80]
2 Proportion ulcers completely
healed at 3 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Proportion ulcers completely
healed at 7 or 8 weeks
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Losses as failures 5 341 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.00, 1.96]
3.2 Complete case analysis 5 290 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.98, 1.88]
4 Proportion of ulcers completely
healed at 12 weeks
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 High-frequency US (losses
as failures)
2 152 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.99, 2.20]
4.2 High-frequency US
(complete case analysis)
2 114 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.94, 1.93]
Comparison 3. Low frequency US vs no ultrasound
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion ulcers completely
healed at 8 - 12 weeks
2 61 Risk Ratio (M-H, Fixed, 95% CI) 3.91 [0.47, 32.85]
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Analysis 1.1. Comparison 1 Ultrasound (any frequency) vs no ultrasound, Outcome 1 Proportion of ulcers
healed at 7 or 8 weeks.
Review: Therapeutic ultrasound for venous leg ulcers
Comparison: 1 Ultrasound (any frequency) vs no ultrasound
Outcome: 1 Proportion of ulcers healed at 7 or 8 weeks
Study or subgroup US no US Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Callam 1987 23/52 14/56 1.77 [ 1.02, 3.06 ]
Dolibog 2008 10/33 12/37 0.93 [ 0.47, 1.87 ]
Eriksson 1991 6/19 4/19 1.50 [ 0.50, 4.48 ]
Lundeberg 1990 5/22 3/22 1.67 [ 0.45, 6.14 ]
Taradaj 2008 12/41 9/40 1.30 [ 0.62, 2.74 ]
Weichenthal 1997 1/19 0/19 3.00 [ 0.13, 69.31 ]
0.002 0.1 1 10 500
Favours No US Favours US
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Analysis 2.1. Comparison 2 High frequency US vs no ultrasound, Outcome 1 Proportion of ulcers
completely healed during study follow up (varying durations of follow up).
Review: Therapeutic ultrasound for venous leg ulcers
Comparison: 2 High frequency US vs no ultrasound
Outcome: 1 Proportion of ulcers completely healed during study follow up (varying durations of follow up)
Study or subgroup US No US Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Callam 1987 25/52 17/56 38.1 % 1.58 [ 0.97, 2.58 ]
Dolibog 2008 10/33 12/37 18.7 % 0.93 [ 0.47, 1.87 ]
Eriksson 1991 6/19 4/19 7.5 % 1.50 [ 0.50, 4.48 ]
Franek 2004 4/43 1/22 2.0 % 2.05 [ 0.24, 17.23 ]
Lundeberg 1990 10/22 8/22 17.5 % 1.25 [ 0.61, 2.56 ]
Taradaj 2008 12/41 9/40 16.2 % 1.30 [ 0.62, 2.74 ]
Total (95% CI) 210 196 100.0 % 1.34 [ 0.99, 1.80 ]
Total events: 67 (US), 51 (No US)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.72, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.059)
0.01 0.1 1 10 100
Favours no US Favours US
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Analysis 2.2. Comparison 2 High frequency US vs no ultrasound, Outcome 2 Proportion ulcers completely
healed at 3 weeks.
Review: Therapeutic ultrasound for venous leg ulcers
Comparison: 2 High frequency US vs no ultrasound
Outcome: 2 Proportion ulcers completely healed at 3 weeks
Study or subgroup US No US Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Franek 2004 4/43 1/22 2.05 [ 0.24, 17.23 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (US), 1 (No US)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours no US Favours US
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Analysis 2.3. Comparison 2 High frequency US vs no ultrasound, Outcome 3 Proportion ulcers completely
healed at 7 or 8 weeks.
Review: Therapeutic ultrasound for venous leg ulcers
Comparison: 2 High frequency US vs no ultrasound
Outcome: 3 Proportion ulcers completely healed at 7 or 8 weeks
Study or subgroup US No US Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Losses as failures
Callam 1987 23/52 14/56 33.0 % 1.77 [ 1.02, 3.06 ]
Dolibog 2008 10/33 12/37 27.7 % 0.93 [ 0.47, 1.87 ]
Eriksson 1991 6/19 4/19 9.8 % 1.50 [ 0.50, 4.48 ]
Lundeberg 1990 5/22 3/22 7.3 % 1.67 [ 0.45, 6.14 ]
Taradaj 2008 12/41 9/40 22.3 % 1.30 [ 0.62, 2.74 ]
Subtotal (95% CI) 167 174 100.0 % 1.40 [ 1.00, 1.96 ]
Total events: 56 (US), 42 (No US)
Heterogeneity: Chi2 = 2.12, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 Complete case analysis
Callam 1987 23/41 14/41 33.8 % 1.64 [ 0.99, 2.72 ]
Dolibog 2008 10/33 12/37 27.3 % 0.93 [ 0.47, 1.87 ]
Eriksson 1991 6/12 4/13 9.3 % 1.63 [ 0.60, 4.38 ]
Lundeberg 1990 5/17 3/15 7.7 % 1.47 [ 0.42, 5.14 ]
Taradaj 2008 12/41 9/40 22.0 % 1.30 [ 0.62, 2.74 ]
Subtotal (95% CI) 144 146 100.0 % 1.36 [ 0.98, 1.88 ]
Total events: 56 (US), 42 (No US)
Heterogeneity: Chi2 = 1.81, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
0.002 0.1 1 10 500
Favours no US Favours US
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Analysis 2.4. Comparison 2 High frequency US vs no ultrasound, Outcome 4 Proportion of ulcers
completely healed at 12 weeks.
Review: Therapeutic ultrasound for venous leg ulcers
Comparison: 2 High frequency US vs no ultrasound
Outcome: 4 Proportion of ulcers completely healed at 12 weeks
Study or subgroup US No US Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-frequency US (losses as failures)
Callam 1987 25/52 17/56 67.2 % 1.58 [ 0.97, 2.58 ]
Lundeberg 1990 10/22 8/22 32.8 % 1.25 [ 0.61, 2.56 ]
Subtotal (95% CI) 74 78 100.0 % 1.47 [ 0.99, 2.20 ]
Total events: 35 (US), 25 (No US)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
2 High-frequency US (complete case analysis)
Callam 1987 25/41 17/41 66.7 % 1.47 [ 0.95, 2.28 ]
Lundeberg 1990 10/17 8/15 33.3 % 1.10 [ 0.59, 2.05 ]
Subtotal (95% CI) 58 56 100.0 % 1.35 [ 0.94, 1.93 ]
Total events: 35 (US), 25 (No US)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
0.002 0.1 1 10 500
Favours No US Favours US
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Analysis 3.1. Comparison 3 Low frequency US vs no ultrasound, Outcome 1 Proportion ulcers completely
healed at 8 - 12 weeks.
Review: Therapeutic ultrasound for venous leg ulcers
Comparison: 3 Low frequency US vs no ultrasound
Outcome: 1 Proportion ulcers completely healed at 8 - 12 weeks
Study or subgroup US No US Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Peschen 1997 2/12 0/12 49.4 % 5.00 [ 0.27, 94.34 ]
Weichenthal 1997 1/19 0/18 50.6 % 2.85 [ 0.12, 65.74 ]
Total (95% CI) 31 30 100.0 % 3.91 [ 0.47, 32.85 ]
Total events: 3 (US), 0 (No US)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
0.001 0.01 0.1 1 10 100 1000
Favours no US Favours US
A P P E N D I C E S
Appendix 1. Search strategy for the original review 1999
For the original review the Cochrane Wounds Group Specialised Register was searched for RCTs of therapeutic ultrasound until
December 1999. The reference lists of reviews and papers obtained from this search were scrutinised to identify additional studies.
Appendix 2. Search strategy for the first update 2007
For the original review the Cochrane Wounds Group Specialised Register was searched for RCTs of therapeutic ultrasound until
December 1999. The reference lists of reviews and papers obtained from this search were scrutinised to identify additional studies.
For this update we performed a search of the Cochrane Wounds Group Specialised Register (last searched 10/08/07). Trials on the
register are identified by hand searching of relevant journals, conference proceedings, and searching electronic databases. We carried
out an additional search of the following electronic databases:
The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library Issue 3, 2007
Ovid MEDLINE - 1950 to July Week 4 2007
Ovid EMBASE - 1980 to 2007 Week 31
Ovid CINAHL - 1982 to August Week 1 2007
We searched The Cochrane Central Register of Controlled Trials (CENTRAL) using the following strategy, which was adapted for
other databases where appropriate:
#1 MeSH descriptor Varicose Ulcer explode all trees
#2 MeSH descriptor Leg Ulcer explode all trees
#3 (varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg NEXT ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*)
#4 (#1 OR #2 OR #3)
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#5 MeSH descriptor Ultrasonic Therapy explode all trees
#6 ultrasound NEAR/5 therap*
#7 ultrason* NEAR/5 therap*
#8 (#5 OR #6 OR #7)
#9 (#4 AND #8)
TheMEDLINE searchwas combinedwith theCochrane highly sensitive search strategy for identifying reports of randomized controlled
trials (Higgins 2005). The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate
Guidelines Network (SIGN).
We contacted researchers to obtain any unpublished data when needed. Reference lists of potentially useful articles were also searched.
There was no restriction by language, date or publication status.
Appendix 3. Ovid MEDLINE search strategy
1 exp Leg Ulcer/
2 (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet adj ulcer*) or stasis ulcer* or (lower extremit* adj ulcer*) or crural
ulcer* or ulcus cruris).tw.
3 or/1-2
4 exp Ultrasonic Therapy/
5 (ultrasound adj5 therap*).tw.
6 (ultrason* adj5 therap*).tw.
7 or/4-6
8 3 and 7
Appendix 4. Ovid EMBASE search strategy
1 exp Leg Ulcer/
2 (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet adj ulcer*) or stasis ulcer* or (lower extremit* adj ulcer*) or crural
ulcer* or ulcus cruris).tw.
3 or/1-2
4 exp Ultrasonic Therapy/
5 (ultrasound adj5 therap*).tw.
6 (ultrason$ adj5 therap*).tw.
7 or/4-6
8 3 and 7
Appendix 5. EBSCO CINAHL search strategy
s10 S4 and S9
S9 S5 or S6 or S7 or S8
S8 TI ultrason* N5 therap* or AB ultrason* N5 therap*
S7 TI ultrasound N5 therap* or AB ultrasound N5 therap*
S6 (MH “Ultrasonics”)
S5 (MH “Ultrasonic Therapy”)
S4 S1 or S2 or S3
S3 TI lower extremity N3 ulcer* or AB lower extremity N3 ulcer*
S2 TI (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet N1 ulcer*) or stasis ulcer* or crural ulcer*) or AB (varicose
ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet N1 ulcer*) or stasis ulcer* or crural ulcer*)
S1 (MH “Leg Ulcer+”)
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Appendix 6. Criteria for judgments for the sources of bias
1. Was the allocation sequence randomly generated?
Yes, low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
No, high risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of ‘Yes’ or ‘No’.
2. Was the treatment allocation adequately concealed?
Yes, low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
No, high risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of randomnumbers); assignment envelopes were usedwithout appropriate
safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of ‘Yes’ or ‘No’. This is usually the case if the method of concealment is not described
or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it
remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding was knowledge of the allocated interventions adequately prevented during the study?
Yes, low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
41Therapeutic ultrasound for venous leg ulcers (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
No, high risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Any one of the following:
• Insufficient information to permit judgement of ‘Yes’ or ‘No’.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Yes, low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
No, high risk of bias
Any one of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Any one of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of ‘Yes’ or ‘No’ (e.g. number randomized not stated, no
reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Yes, low risk of bias
Any of the following:
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• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon)
No, high risk of bias
Any one of the following:
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of ‘Yes’ or ‘No’. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias:
Yes, low risk of bias
The study appears to be free of other sources of bias.
No, high risk of bias
There is at least one important risk of bias. For example, the study:
• Had a potential source of bias related to the specific study design used; or
• Stopped early due to some data-dependent process (including a formal-stopping rule); or
• Had extreme baseline imbalance; or
• Has been claimed to have been fraudulent; or
• Had some other problem.
Unclear
There may be a risk of bias, but there is either:
• Insufficient information to assess whether an important risk of bias exists; or
• Insufficient rationale or evidence that an identified problem will introduce bias.
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WH A T ’ S N E W
Last assessed as up-to-date: 7 May 2010.
Date Event Description
9 November 2011 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 4, 2000
Date Event Description
7 May 2010 New citation required and conclusions have changed The review has been substantially re-written and re-
structured. We have re-structured the review to distin-
guish high and low frequency ultrasound. We have also
added a summary of findings table
7 May 2010 New search has been performed New searches have been conducted and two new studies
added to the review (Dolibog 2008; Taradaj 2008). Two
previously included trials have now been excluded as
theywere quasi-randomised (Dyson 1976;Roche 1984)
.
30 April 2008 Amended Converted to new review format.
2 November 2007 New citation required and conclusions have changed Substantive amendment.
For this first update, new searches were carried out in
August 2007 and one new trial met the inclusion criteria
for the review (Franek 2004). Additional citations were
identified for existing trials and these were added to
the appropriate reference lists. One trial (Franek 2006)
is currently awaiting assessment, it has been translated
but clarification has been sought from the author as to
whether this trial is a further publication of Franek 2004
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